drugset / Trial / NCT02510781
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
RandomizedParallel-groupOpen-labelTreatment
Summary
Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（HER-2）positive. The investigators witnessed a higher pathological complete remission(pCR) rate but no obvious increase in cardiac toxicity when used the anthracycline instead of carboplatin. The investigators expect to carry out a large sample size clinical research to optimize the existing therapeutic regimen
Timeline
- Start
- 2015-01
- Primary completion
- 2016-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Epirubicin | Small molecule | 75 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |